BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
More details
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episodes
Page 8 · 50 per pageEp. 21 - FDA’s Credibility on the Line, plus Biotech’s Venture Wave
More description
Listen elsewhere
Ep. 15 - Vaccine Hopes, the Shifting Biopharma Workplace & Blueprint's Dx Deal
More description
Listen elsewhere
Ep. 12 - Remdesivir's Price, RWD’s Moment & A Genomics Breakup
More description
Listen elsewhere
Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics
More description
Listen elsewhere
Ep. 5 - Master Protocols, EUAs and Rick Bright: BioCentury editors on COVID-19
More description
Listen elsewhere
BioCentury editors discuss Goldilocks COVID-19 antibody test regulation, vaccine development, and the post-pandemic future.
More description
BioCentury editors discuss Goldilocks COVID-19 antibody test regulation, vaccine development, and the post-pandemic future.
Listen elsewhere
BioCentury Editors discuss what the latest survey results tell us about how biotechs are managing through the economic downturn, and cover what FDA Commissioner Hahn told BioCentury last week.
More description
BioCentury Editors discuss what the latest survey results tell us about how biotechs are managing through the economic downturn, and cover what FDA Commissioner Hahn told BioCentury last week.
Listen elsewhere
How industry, government and academics are joining together to discover, develop and deploy therapies and vaccines.
More description
How industry, government and academics are joining together to discover, develop and deploy therapies and vaccines.
Listen elsewhere
It has been three months since Chinese scientists revealed the genomic sequence of SARS-CoV-2. In our first episode, “Racing to Create Countermeasures,” BioCentury’s editors discuss progress made by biopharma companies and other researchers in developing diagnostics, therapies and vaccines against the virus that causes COVID-19.
More description
It has been three months since Chinese scientists revealed the genomic sequence of SARS-CoV-2. In our first episode, “Racing to Create Countermeasures,” BioCentury’s editors discuss progress made by biopharma companies and other researchers in developing diagnostics, therapies and vaccines against the virus that causes COVID-19.